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Filaggrin’s Fuller Figure: A Glimpse into 
the Genetic Architecture of Atopic 
Dermatitis
Aileen Sandilands1, Frances J. D. Smith1, Alan D. Irvine2,3 and 
W. H. Irwin McLean1
Prevalent mutations in the FLG gene underlie the common skin disorder ichthyosis 
vulgaris and are significant risk factors for atopic dermatitis (eczema). The recent 
publication of a strategy to sequence this difficult gene identifies a spectrum of 
both prevalent and rare mutations that collectively have a significant impact on 
susceptibility to atopic disease.
Journal of Investigative Dermatology (2007) 127, 1282–1284. doi:10.1038/sj.jid.5700876
The FLG gene encodes profilaggrin, a 
protein that is essential for the forma-
tion and hydration of the skin barrier 
(Figure 1). We have previously demon-
strated that null mutations in the FLG 
gene cause the common keratinizing 
disorder ichthyosis vulgaris (IV) (Smith 
et al., 2006). IV is characterized by dry, 
scaly skin and is often associated with 
atopic dermatitis (AD), which in some 
families is inherited as a secondary trait 
but with lower penetrance (Sandilands et 
al., 2006). Furthermore, we have shown 
that filaggrin is a major susceptibility 
gene for AD and that two highly preva-
lent null mutations in the beginning of 
the FLG gene (R501X and 2282del4) 
significantly predispose European 
individuals to early-onset, severe, and 
persistent AD and also to the form 
of asthma that is associated with AD 
(Palmer et al., 2006). These results were 
replicated in several other European 
case–control association studies with 
similar conclusions, firmly establishing 
the importance of skin barrier dysfunc-
tion in the development of AD and asso-
ciated atopic disease (Irvine, 2007). To 
complete the story, we needed to devel-
op a sequencing strategy that would 
allow us to routinely sequence the 
remainder of the FLG gene to uncover 
a fuller spectrum of mutations and their 
collective contribution to AD.
The FLG gene, like other members of 
the S100 “fused-type” gene family, such 
as hornerin, trichohyalin, and repetin, 
shares a conserved gene structure consist-
ing of three exons and two introns (Gan 
et al., 1990). The initiation codon is locat-
ed in exon 2, whereas the bulk of the pro-
filaggrin polyprotein is encoded by exon 
3. Sequencing of exon 3 is problematic, 
not only because of its size (>12 kb) but 
also because it consists of between 10 
and 12 tandemly arranged filaggrin repeat 
units. Although exon 3 in its entirety can 
be amplified using a long-range PCR, it is 
not possible to sequence this large frag-
ment because of its repetitive nature. 
Each filaggrin repeat unit is of similar size 
(~1 kb) and because only a small num-
ber of bases occur in each repeat that 
are unique, the choice of suitable primer 
sites for amplification and sequencing is 
severely restricted. In filaggrin repeats 7, 
8, and 9 there are no absolutely specific 
bases, making this the most difficult area 
to analyze. Moreover, we have found that 
many of those bases that are apparently 
unique to a particular filaggrin repeat are 
in fact polymorphic, limiting the choice 
of suitable primer sites even further. 
Consequently, allele dropout can occur 
during PCR amplification if the primer 
is inadvertently designed around one of 
these polymorphic bases.
Despite these difficulties, we have 
developed an overlapping PCR strategy 
that permits routine and comprehensive 
sequencing of exon 3 of the FLG gene 
(Sandilands et al., 2007). During the 
development of this strategy we used 
single-nucleotide polymorphisms to 
our advantage; not only did they con-
firm that the PCR fragments we gener-
ated were indeed overlapping but they 
also indicated if one allele had failed 
to amplify. Using this approach we 
sequenced a selection of individuals of 
European origin who had a severe IV 
phenotype and were already heterozy-
gous for either R501X or 2282del4, sug-
gesting to us the presence of secondary, 
compound heterozygous mutations. 
Sequencing of these individuals identi-
fied seven additional null mutations in 
the FLG gene (Sandilands et al., 2007). 
Three of these new mutations were 
recurrent. All the FLG mutations we have 
identified to date are either small dele-
tions, leading to frameshifts and prema-
ture stop codons, or nonsense mutations 
(Figure 1). Histologically and biochemi-
cally, individuals who have one of these 
more distal mutations express a trun-
cated profilaggrin species that is capa-
ble of forming a granular layer within 
the epidermis, albeit greatly reduced in 
size. Importantly, however, these trun-
cated profilaggrin species are not pro-
cessed into functional filaggrin subunits 
(Sandilands et al., 2007). Thus, mutations 
that occur in the more distal filaggrin 
repeats are of similar or equal pathoge-
nicity in terms of IV to those mutations 
that occur in the first or second filag-
grin repeats. Preliminary data suggest 
that there may be some differences in 
the observed penetrance with respect to 
AD between the more distal mutations, 
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the stage is now set 
for the identifi cation 
of FLG mutations in 
different ancestral groups 
worldwide
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although all significantly contribute 
to the pathogenesis of AD (Sandilands 
et al., 2007).
Having identified these new FLG muta-
tions, we also screened a case series of 
188 Irish children with early-onset mod-
erate to severe AD for these new variants. 
Together with the prevalent mutations 
R501X and 2282del4, a highly signifi-
cant association was obtained (P = 2.12 
× 10−51). In addition, we also sequenced 
a handful of individuals with severe AD 
from this well-characterized case series 
and identified three further mutations 
(Sandilands et al., 2007). Overall, the pic-
ture beginning to emerge from our labora-
tory suggests that the genetic architecture 
of filaggrin-related AD consists of a mix-
ture of several prevalent FLG mutations 
coupled with the addition of multiple 
rarer, perhaps even family-specific, muta-
tions. To determine the exact contribution 
these rare mutations make cumulatively 
to AD would require the considerable 
and rather costly effort of fully sequenc-
ing every individual from such a case 
series. Nevertheless, such an approach 
has proved successful elsewhere in iden-
tifying multiple, low-frequency alleles 
that determine the blood plasma levels 
of high-density lipoprotein cholesterol, a 
significant risk factor for coronary heart 
disease (Cohen et al., 2004).
Distinct size variants of the FLG gene 
exist, with individuals carrying 10, 11, 
or 12 filaggrin repeats (Gan et al., 1990). 
Using our sequencing strategy we identi-
fied the position and sequence of these 
extra filaggrin repeats. At least four dis-
tinct size variants of the FLG gene exist, 
depending on which repeats are duplicat-
ed (Sandilands et al., 2007). Individuals 
may be homozygous or heterozygous 
for these different sized variants. It is 
unclear why there is such variability in 
the overall number of filaggrin repeats; 
however, a rather simplistic answer may 
be that extra filaggrin repeats, and hence 
extra filaggrin protein, may strengthen 
the barrier properties of the skin under 
certain environmental stresses. Indeed, 
one study has suggested that an inverse 
association exists between the number 
of filaggrin repeats and self-perceived dry 
skin (Ginger et al., 2005). However, this 
series was not typed for FLG mutations 
and so it is probable that a significant 
proportion will carry FLG null mutations 
as well. Although filaggrin repeat length 
variability in our AD series has yet to be 
ascertained, it is possible that the pen-
etrance and/or severity of AD could be 
modulated in those heterozygous carri-
ers who carry these longer sized variants 
on the unaffected allele.
FLG mutations R501X and 2282del4, 
although prevalent in individuals of 
European ancestry, are rare or absent 
from other populations (Palmer et al., 
2006). Therefore, to assess the extent to 
which FLG mutations contribute to AD in 
a global context we must identify muta-
tions in other ancestral groups. The publi-
cation of our sequencing strategy should 
help to facilitate this process. Indeed, our 
strategy has already been successfully 
used to identify two novel FLG mutations 
in Japanese IV patients, the first non-
European FLG mutations to be described 
(Nomura et al., 2007). Within a small 
case series of Japanese AD patients, 
both mutations show a statistically sig-
nificant association with AD (Nomura 
et al., 2007). We also know that one of 
these mutations (3321delA, found in 
the second filaggrin repeat) is prevalent 
in the Chinese population, with a car-
rier frequency of ~3.6% (Sandilands et 
al., 2007). Although the statistical asso-
ciation of mutation 3321delA with AD 
in the Chinese population remains to be 
determined, based on our experiences 
with the common European mutations 
it is predicted to be significant. Thus, 
the stage is now set for the identification 
of FLG mutations in different ancestral 
groups worldwide so the cumulative 
global contribution of these different 
variants to AD can be measured.
Approximately half of our Irish 
AD case series carries FLG null muta-
tions (Sandilands et al., 2007). New 
mutations, identified through direct 
sequencing of individual cases, will 
undoubtedly increase this figure further, 
but what about the remainder? What 
other genes confer susceptibility to AD? 
The epidermal differentiation complex 
(EDC) on chromosome 1q21, where the 
filaggrin gene is located, is a shared sus-
ceptibility loci for both AD and psoriasis 
(Giardina et al., 2006). The EDC contains 
a dense cluster of genes, such as loricrin, 
trichohyalin, and involucrin, all of which 
play a role in the terminal differentiation 
of the epidermis. By genotyping carefully 
characterized AD case series and popu-
lation-based cohorts, carriers of FLG 
null mutations can be removed, creating 
residual, “nonfilaggrin” datasets that may 
Figure 1. The reported loss-of-function FLG mutations and size variants mapped onto the profilaggrin 
protein structure. (a) A diagram of the human profilaggrin molecule showing the positions of the 15 
reported loss-of-function mutations reported in FLG. The domain structure is as follows: S100 calcium 
binding domain (green); B-domain (yellow); imperfect filaggrin repeats (light blue); filaggrin repeats (red); 
C-terminal domain (black). Variants shown above the molecule were initially identified in individuals of 
European ancestry with ichthyosis vulgaris and/or atopic dermatitis. The variants shown in red are prevalent; 
those in black are either very rare or family-specific. Those shown below the protein were initially identified 
in the Japanese population; however, 3321delA was also carried by 3.6% of the Chinese population. 
(Reprinted from Sandilands et al., 2007.) (b) The characterized size variants of the filaggrin gene. Two 
11-repeat alleles result from duplication of either repeat 8 or repeat 10. A 12-repeat allele results from 
duplication of both repeats 8 and 10. It is likely that size variants involving other repeats are also present in 
the human population. Duplicated filaggrin repeats are shown in gray.
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well be more informative and useful for 
the identification of other AD suscepti-
bility genes (Morar et al., 2007).
The picture that is beginning to 
emerge from our research suggests that 
the genetic architecture of AD is com-
posed of a complex mixture of prevalent 
FLG mutations and a large number of 
low-frequency mutations, which, when 
combined, have a significant influence 
on AD susceptibility.
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Common Ground?: Tetracyclines, 
Matrix Metalloproteinases, Pustular 
Dermatoses, and Loxoscelism
Lloyd E. King, Jr.1
The fear of spiders is ancient and common throughout much of the world. Skin 
ulceration and necrosis due to Loxosceles spider envenomation (“bites”) is 
among the best known sequelae of a usually accidental encounter. Therapies for 
Loxosceles envenomations either are not well documented or have adverse side 
effects that limit their use by generalists. Based on in vitro and in vivo studies 
in rabbits injected with purified or recombinant sphingomyelinase D2, Paixão-
Cavalcante et al. (2007) propose in this issue that topical tetracyclines could 
become safe, efficacious therapy for cutaneous loxoscelism.
Journal of Investigative Dermatology (2007) 127, 1284–1286. doi:10.1038/sj.jid.5700724
The tetracycline family is used to treat 
more than 30 dermatoses (Lebwohl et 
al., 2002) and may be useful in treating 
cutaneous Loxosceles envenomation. In 
perspective, prescribing tetracyclines in 
clinical practices varies from anecdotal 
reports to well-controlled, double-blind 
studies in large numbers of patients 
(Lebwohl et al., 2002). Off-label, empir-
ical therapy based on efficacious, safe 
clinical outcomes in treating benign 
and clinically severe pustular, bullous, 
and scarring dermatoses is so common 
that most dermatologists are not very 
concerned about using tetracyclines in 
this way. The mechanisms of how tetra-
cyclines generate their non-antimicro-
bial effects in acne vulgaris and other 
dermatoses are not well understood. 
The data of Paixão-Cavalcante et al., 
2007 (this issue) on Loxosceles sphin-
gomyelinase D2 (SMD2) and matrix 
metalloproteinases (MMPs) provide 
new insights into the pathophysiology 
of pustular dermatoses.
MMPs also have a broad spectrum 
of biological effects in various cutane-
ous and systemic disorders, including 
acneiform conditions with scarring, 
wound healing, carcinomas with and 
without metastases, and immuno-
logical disorders. For example, an 
MMP inhibitor, COL-3, has been 
used to treat AIDS-related Kaposi’s 
sarcoma (Cianfrocca et al., 2002). 
Understanding how the many forms 
of MMPs are regulated in normal and 
abnormal developing and differenti-
ated tissues is key to developing new 
therapeutic approaches, as implied by 
Paixão-Cavalcante et al. (2007).
What do MMPs and tetracyclines 
have to do with Loxosceles spider bites? 
The authors propose that topical tetra-
cyclines, via divalent cation chelation, 
inhibit the Loxosceles venom enzyme 
responsible for dermonecrosis, SMD2. 
This SMD2 inhibition decreased MMP2 
and MMP9 expression, increased 
in vitro cell viability, and inhibited 
or reduced skin ulceration in vivo. 
In previous studies cited by Paixão-
Cavalcante et al. (2007), the authors 
found that activated MMP(s) cleaved 
membrane-bound receptors such as 
EGFR, glycophorin, and other receptors 
involved in signal pathways including 
apoptosis and cell death (Tambourgi 
et al., 2000; Van den Berg et al., 2002). 
Such receptor proteolysis may partially 
explain why severe Loxosceles-induced 
skin ulcers are very slow to heal (Sams 
et al., 2001). The current studies do not 
address platelet activation, aggrega-
tion, and thrombosis by SMD2 only in 
the presence of acute phase reactants 
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